BIOCELTIX S.A. ZY -10 Cash Flow-to-Debt Ratio
BIOCELTIX S.A. ZY -10 cash flow-to-debt ratio. BIOCELTIX S.A. ZY -10 (XI3) has a Cash Flow-to-Debt Ratio of -1.93x as of December 2025, meaning its operating cash flow of €-4.54 Million could theoretically repay -2% of its total liabilities (€2.36 Million) in one year. See XI3 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of BIOCELTIX S.A. ZY -10 (2021–2025)
Cash flow-to-debt ratio of BIOCELTIX S.A. ZY -10 from 2021 to 2025. Historical debt coverage capacity for BIOCELTIX S.A. ZY -10 across 5 annual periods. Also explore BIOCELTIX S.A. ZY -10 (XI3) equity growth momentum to track the company's year-over-year net asset growth rate.
BIOCELTIX S.A. ZY -10 Cash Flow-to-Debt Ratio by Year (2021–2025)
BIOCELTIX S.A. ZY -10 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for BIOCELTIX S.A. ZY -10. For the full cash flow conversion analysis, see BIOCELTIX S.A. ZY -10 (XI3) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.07x | €-11.95 Million | €2.36 Million | ▲ +0.8% |
| 2024 | -5.11x | €-17.57 Million | €3.44 Million | ▲ +21.4% |
| 2023 | -6.50x | €-14.75 Million | €2.27 Million | ▼ -106.6% |
| 2022 | -3.15x | €-7.87 Million | €2.50 Million | ▼ -72.0% |
| 2021 | -1.83x | €-4.02 Million | €2.20 Million | — |